BioGaia AB has been granted a European patent for the use of the company's health-promoting bacterium Reuteri, in pharmaceutical and nutritional products for reducing dehydration in subjects suffering from acute diarrhoea and vomiting. The patent is valid until 2016.
The patent is based on several published clinical studies that show Reuteri's unique ability to significantly reduce problems that occur with severe diarrhoea.
This new patent strengthens the protection of our products in the gut health area, in particular Reuteri Drops and Reuteri Tablets which are sold in Sweden and a series of other markets around the world, says Peter Rothschild MD BioGaia AB.
BioGaia presently has a total of 79 patents within 18 patent families.